the aid library

LIST OPTIONS

Filter

2300

COVID 19 Strategic preparedness and response plan - Monitoring and evaluation framework

World Health Organization WHO (2021) C_WHO

The COVID-19 Strategic Preparedness and Response Plan (SPRP) 2021 Monitoring and Evaluation Framework tracks global progress against the COVID-19 SPRP 2021 for the ten pillars of the public health response. The operational intelligence complements the epidemiologic information used to drive a global... more

Download (322)

View PDF (321)

Government policy interventions to reduce human antimicrobial use: A systematic review and evidence map

Van Katwyk, S. R.; Grimshaw, J. M.; et al (2019) C2

BACKGROUND: Growing political attention to antimicrobial resistance (AMR) offers a rare opportunity for achieving meaningful action. Many governments have developed national AMR action plans, but most have not yet implemented policy interventions to reduce antimicrobial overuse. A systematic evidenc...e map can support governments in making evidence-informed decisions about implementing programs to reduce AMR, by identifying, describing, and assessing the full range of evaluated government policy options to reduce antimicrobial use in humans. METHODS AND FINDINGS: Seven databases were searched from inception to January 28, 2019, (MEDLINE, CINAHL, EMBASE, PAIS Index, Cochrane Central Register of Controlled Trials, Web of Science, and PubMed). We identified studies that (1) clearly described a government policy intervention aimed at reducing human antimicrobial use, and (2) applied a quantitative design to measure the impact. We found 69 unique evaluations of government policy interventions carried out across 4 of the 6 WHO regions. These evaluations included randomized controlled trials (n = 4), non-randomized controlled trials (n = 3), controlled before-and-after designs (n = 7), interrupted time series designs (n = 25), uncontrolled before-and-after designs (n = 18), descriptive designs (n = 10), and cohort designs (n = 2). From these we identified 17 unique policy options for governments to reduce the human use of antimicrobials. Many studies evaluated public awareness campaigns (n = 17) and antimicrobial guidelines (n = 13); however, others offered different policy options such as professional regulation, restricted reimbursement, pay for performance, and prescription requirements. Identifying these policies can inform the development of future policies and evaluations in different contexts and health systems. Limitations of our study include the possible omission of unpublished initiatives, and that policies not evaluated with respect to antimicrobial use have not been captured in this review. CONCLUSIONS: To our knowledge this is the first study to provide policy makers with synthesized evidence on specific government policy interventions addressing AMR. In the future, governments should ensure that AMR policy interventions are evaluated using rigorous study designs and that study results are published. more

Download (1118)

View PDF (1160)

Kerala Antimicrobial Resistance Strategic Action Plan (KARSAP)

Department of Agriculture Development & Farmers Welfare; Health & Family Welfare, Government of Kerala (2018) C1

One health Response to AMR Containment. In a significant move for the public health sector, Kerala has become the first state in India to launch an action plan to combat the growing cases of antimicrobial immunity, arising primarily from irrational use of medicines and excessive antibiotics used in... more

Download (2880)

View PDF (3086)

Philippine National Drug Formulary - Essential Medicines List, Volume I (7th Edition)

The National Formulary Committee, National Drug Policy, DOH Philippines (2008) C1

Download (441)

View PDF (658)

Welttuberkulosetag 2016: Gemeinsam gegen Tuberkulose

Robert Koch Institut (2016) C1

Epidemiologisches Bulletin; 14. März 2016 Nr. 10/11 ;DOI 10.17886/EpiBull-2016-014

Download (465)

View PDF (693)

Therapeutics and COVID-19 (Living Guideline, 10 November 2023)

World Health Organization WHO (2023) C_WHO

WHO has updated its guidelines for COVID-19 therapeutics, with revised recommendations for patients with non-severe COVID-19. This is the 13th update to these guidelines. Updated risk rates for hospital admission in patients with non-severe COVID-19 The guidance includes updated risk rates for... hospital admission in patients with non-severe COVID-19. The current COVID-19 virus variants tend to cause less severe disease while immunity levels are higher due to vaccination, leading to lower risks of severe illness and death for most patients. This update includes new baseline risk estimates for hospital admission in patients with non-severe COVID-19. The new ‘moderate risk’ category now includes people previously considered to be high risk including older people and/or those with chronic conditions, disabilities, and comorbidities of chronic disease. The updated risk estimates will assist healthcare professionals to identify individuals at high, moderate or low risk of hospital admission, and to tailor treatment according to WHO guidelines: **High: **People who are immunosuppressed remain at higher risk if they contract COVID-19, with an estimated hospitalization rate of 6%. **Moderate: **People over 65 years old, those with conditions like obesity, diabetes and/or chronic conditions including chronic obstructive pulmonary disease, kidney or liver disease, cancer, people with disabilities and those with comorbidities of chronic disease are at moderate risk, with an estimated hospitalization rate of 3%. Low: Those who are not in the high or moderate risk categories are at low risk of hospitalization (0.5%). Most people are low risk. Review of COVID-19 treatments for people with non-severe COVID-19 WHO continues to strongly recommend nirmatrelvir-ritonavir (also known by its brand name ‘Paxlovid’) for people at high-risk and moderate risk of hospitalization. The recommendations state that nirmatrelvir-ritonavir is considered the best choice for most eligible patients, given its therapeutic benefits, ease of administration and fewer concerns about potential harms. Nirmatrelvir-ritonavir was first recommended by WHO in April 2022. If nirmatrelvir-ritonavir is not available to patients at high-risk of hospitalization, WHO suggests the use of molnupiravir or remdesivir instead. WHO suggests against the use of molnupiravir and remdesivir for patients at moderate risk, judging the potential harms to outweigh the limited benefits in patients at moderate risk of hospital admission. For people at low risk of hospitalization, WHO does not recommend any antiviral therapy. Symptoms like fever and pain can continue to be managed with analgesics like paracetamol. WHO also recommends against use of a new antiviral (VV116) for patients, except in clinical trials. The update also includes a strong recommendation against the use of ivermectin for patients with non-severe COVID-19. WHO continues to advise that in patients with severe or critical COVID-19, ivermectin should only be used in clinical trials. more

Download (509)

View PDF (724)

When the Drugs Don’t Work – Antibiotic Resistance as a Global Development Problem

The Dag Hammarskjöld Foundation and ReAct (2019) C2

This paper focuses on the Sustainable Development Goals related to poverty, economic growth, inequality, health, food production and the environment. It presents concrete examples of the underlying and complex aspects of antibiotic resistance and its impacts across different Sustainable Development ... more

Download (272)

View PDF (589)

UNODC-WHO Stop-Overdose-Safely (‎S-O-S)‎ project implementation in Kazakhstan, Kyrgyzstan, Tajikistan and Ukraine

World Health Organization WHO; United Nations Office on Drugs and Crime UNODC (2021) C_WHO

Summary Report

Download (305)

View PDF (484)

COVID-19 in Latin America and the caribbean region: Symptoms and morbidities in the epidemiology of infection

Anaya-Covarrubias, J.Y.; et al. (2022) C1

Curr Opin Pharmacol . 2022 Apr;63:102203.doi: 10.1016/j.coph.2022.102203. Epub 2022 Feb 11. The COVID-19 pandemic has widespread economic and social effects on Latin America (LA) and the Caribbean (CA). This region, which has a high prevalence of chronic diseases, has been one of the most affected... more

Download (353)

View PDF (350)

ECOSOC Meeting “Addressing noncommunicable diseases and mental health: major challenges to sustainable development in the 21st century”

World Health Organization (2009) C_WHO

Discussion Paper "Mental health, poverty and development", July 2009

Download (327)

View PDF (277)

Standard treatment guidelines neurology (India)

Ministry of Health & Family Welfare, India (2020) C1

Accessed Febr. 6, 2020

Download (250)

View PDF (308)

WHO Report on the Global Tobacco Epidemic, 2019. Offering help to quit tobacco use

World Health Organization WHO (2019) C_WHO

The seventh WHO Report on the global tobacco epidemic analyses national efforts to implement the most effective measures from the WHO Framework Convention on Tobacco Control (WHO FCTC) that are proven to reduce demand for tobacco. The report showed that while only 23 countries have implemented ce... more

Download (317)

View PDF (437)

PAHO’s Health Emergency Appeal 2023

World Health Organisation (WHO) (2023) C_WHO

This document outlines PAHO’s regional priorities for the year 2023 to sustain and scale up health emergency and humanitarian assistance in the Americas, with a focus on five priority countries currently facing a prolonged humanitarian crisis and recovering from recent acute emergencies: Colombia,... more

Download (212)

View PDF (419)

Recomendações para o manejo da asma da Sociedade Brasileira de Pneumologia e Tisiologia – 2020

Menezes Pizzichini, M. M.; de Carvalho-Pinto, R. M.; Delfini Cançado, J. E.; et al. (2020) CC2

The pharmacological management of asthma has changed considerably in recent decades, as it has come to be understood that it is a complex, heterogeneous disease with different phenotypes and endotypes. It is now clear that the goal of asthma treatment should be to achieve and maintain control of the... more

Download (253)

View PDF (209)

Panorama of Diabetes in the Americas by Pan American Health Organization

Pan American Health Organization PAHO (2022) C_WHO

The burden of diabetes is enormous, positioning it as one of the main challenges facing public health today. Currently, it is estimated that 62 million people are living with diabetes in the Region of the Americas and projections show its prevalence will continue rising over the following years. The... more

Download (854)

View PDF (1229)

Zambia Health Statistics Profile 2010

World Health Organization; Regional Office for Africa (2011) C_WHO

Download (280)

View PDF (274)

TB and HIV concept note - Investing for impact against tuberculosis and HIV

The Global Fund To fight AIDS, Tuberculosis and Malaria (2015) C2

Single TB and HIV Concept Note Albania 2016-2018 27 April 2015

External Link

The cost of inaction on health equity and its social determinants

Yerramilli P., Chopra M., Rasanathan K. BMJ Global Health (2024) CC

Rising levels of inflation, debt and macrofiscal tightening are putting expenditures on the social sectors including health under immense scrutiny. Already, there are worrying signs of reductions in social sector investments. However, even before the pandemic, evidence showed the significant returns... more

Download (344)

View PDF (307)

Regional Status Report on Alcohol and Health in the Americas 2020

Pan American Health Organisation PAHO (2020) C_WHO

This third regional report discusses gaps and challenges in reducing the harmful use of alcohol and how countries can reverse current trends in a cost-effective and expedited way.

Download (629)

View PDF (861)

Accelerating WHO FCTC Implementation in the WHO South-East Asia Region: A Practical Approach

World Health Organization (WHO), Regional Office for South-East-Asia (2017) C_WHO

The WHO Framework Convention on Tobacco Control (‎WHO FCTC)‎ is an evidence-based treaty that reaffirms the right of all people to the highest standard of health and was developed in response to the globalization of the tobacco epidemic. Member States of the WHO South-East Asia Region have made... more